Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,510

Document Document Title
WO/2019/020104A1
The present invention falls within the field of preparation methods for pharmaceutical compounds, and in particular relates to preparation and analysis methods of a benzimidazole derivative. The methods comprise recrystallizing and pulpi...  
WO/2019/020987A1
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The compounds in question are of formula II and comprise a spirofused tricycle core: wherein R4 and R5 together with the carbon atom t...  
WO/2019/023417A1
The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.  
WO/2019/022061A1
This fungicide for agricultural and horticultural use includes a compound represented by formula (I) (in the formula, X represents a halogen group, etc.; n represents any integer of 0-4; when n is 2 or higher, X may be the same or differ...  
WO/2019/015559A1
The present invention belongs to the field of medical chemistry, and relates to a class of heterocyclic compounds acting as ASK inhibitors and the use thereof. Specifically, provided are compounds as shown in formula A or isomers, pharma...  
WO/2019/016679A1
A novel combination comprising the integrase strand transfer inhibitor, cabotegravir or a pharmaceutically acceptable salt or solvate thereof, with the nucleoside reverse transcriptase translocation inhibitor EFdA (MK-8591), or a pharmac...  
WO/2019/014305A1
Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use i...  
WO/2019/012063A1
The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.  
WO/2019/011166A1
The invention relates to a macrocyclic amide compound containing a thiophene group, and a preparation method of the macrocyclic amide compound and an intermediate thereof. The invention also relates to the macrocyclic amide compound cont...  
WO/2019/007866A1
The invention relates to a composition comprising an electron-transporting host and a hole transporting host, to the use thereof in electronic devices and electronic devices containing said composition. The electron-transporting host is ...  
WO/2019/002571A1
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...  
WO/2019/006050A1
The present invention describes the combination of a NK1-antagonist with pramipexole or a pharmaceutically acceptable salt or solvate thereof, useful for treating depressive disorders, including major depressive disorder.  
WO/2019/006292A1
The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.  
WO/2019/000224A1
Provided are a bisindolylmaleimide derivative and a preparation method and use thereof. The bisindolylmaleimide derivative has good therapeutic effect on tumors, especially on some drug-resistant tumors, and thus precise treatment of the...  
WO/2019/003076A1
The present invention relates to novel pyrido-imiddazo rifamycines of Formula (I) as defined below and characterized by a highly selective antibacterial activity and low absorption by oral route. (I) wherein R and R1 may be H, (AA) with ...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  
WO/2018/233663A1
Disclosed in the present invention are a thiazolidone spiro pyrimidine trione compound, a preparation method therefor and uses thereof, the compound having a structure represented by formula (I). In the formula, the definitions of the su...  
WO/2018/234978A1
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1) - mediated diseases or disorders, Formula (I), wherein ...  
WO/2018/234343A1
Compounds of Formula (0), and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.  
WO/2018/234807A1
The present invention relates to compounds of formula (I). The compounds may be used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. (I)  
WO/2018/233670A1
Disclosed in the present invention are a benzoisoxazole spiropyrimidinetrione compound, a preparation method therefor and use thereof, said compound having a structure as represented by formula (I). In said formula, the definition of eac...  
WO/2018/233111A1
The present invention provides an environmentally friendly method for preparing levofloxacin hydrochloride, the preparation comprising 3-(2-hydroxy-1-methyl-ethylamino)-2-(2,3,4,5-tetrafluorobenz oyl)-ethyl acrylate, a preparation of lev...  
WO/2018/228934A1
The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical pre...  
WO/2018/229511A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic and M4 receptors. Also provided are pharmaceutical compositions co...  
WO/2018/228907A1
The present invention relates to novel diazabicyclic substituted imidazo[l,2-a]pyrimidine- derivatives, to methods for producing the same, to the use thereof either alone or in combination for the treatment and/or prevention of diseases,...  
WO/2018/230555A1
The present invention provides a compound represented by formula (1)( in formula (I), R1 represents a substituted or unsubstituted C1-6 alkyl group; R2 represents a substituted or unsubstituted C1-8 alkyl group; R3 represents a hydrogen ...  
WO/2018/228909A1
The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment a...  
WO/2018/229798A1
The present invention provides processes and intermediates for the synthesis of bictegravir and its pharmaceutical salt.  
WO/2018/225097A1
The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically acti...  
WO/2018/227058A1
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...  
WO/2018/220355A1
The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquiti...  
WO/2018/222169A3
Disclosed are vanadyl complexes of Formula 1, Formula 2, and Formula 3, wherein R1, R2 and R are defined as in the description. The pharmaceutical compositions containing these complexes and uses of the complexes for treatment of Diabete...  
WO/2018/220542A1
The present invention relates to compounds having structural formula (I) wherein R1 and R2 are defined as set forth in the description. The invention also relates to a process for the manufacture of the above compounds of formula (I), wh...  
WO/2018/220365A1
The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an ...  
WO/2018/222169A2
Disclosed are vanadyl complexes of Formula 1, Formula 2, and Formula 3, wherein Ri, R2, and R are defined as in the description. The pharmaceutical compositions containing these complexes and uses of the complexes for treatment of Diabet...  
WO/2018/217050A1
The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyp...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/214686A1
The present invention discloses a method for preparing an isoxazinone compound (I) and an application thereof. The method and the application thereof comprise: reacting a compound (II) and carboxylic acid (III) under the action of a dehy...  
WO/2018/215318A1
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.  
WO/2018/215668A1
The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative...  
WO/2018/213422A1
The present invention features compounds useful in the treatment of BAF complex related disorders.  
WO/2018/205038A1
Pharmaceutical compositions comprising a mixture of cannabinoids and terpenes and use thereof in the treatment of select disorders mediated by the Hedgehog (HH) signaling pathway are disclosed. In preferred embodiments, the components of...  
WO/2018/206539A1
The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...  
WO/2018/202733A1
The present disclosure is directed to an improved process to convert crude ascomycin to purified pimecrolimus. Crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus, which is the...  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/204416A1
The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.  
WO/2018/203298A1
The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceuti...  
WO/2018/197653A1
The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[ƒ]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula ...  
WO/2018/197447A1
The present invention relates to bridged triarylamines which correspond to a defined formula. Said compounds are suitable for use in electronic devices. The invention also relates to methods for preparing said compounds and to electronic...  
WO/2018/199699A1
The present specification provides a heterocyclic compound of chemical formula 1 and an organic light emitting element comprising the same.  

Matches 1 - 50 out of 13,510